The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Launched by HOSPICES CIVILS DE LYON · Mar 4, 2019
Trial Information
Current as of April 29, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of well-differentiated metastatic neuroendocrine tumour (either synchronous or metachronous)
- • Diagnosis performed between 1 January 1990 and 31 December of 2017
- • Patients seen at least once at the oncologic department of Hospices Civils de Lyon.
- Exclusion Criteria:
- • Poorly differentiated neuroendocrine carcinoma
- • Histologic mixed neuroendocrine tumour
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials